



**Participant Evaluation**  
**LIVE Symposium**  
 "HPV related cancer: biology, Treatment  
 and Innovative approaches"  
 Phoenix, AZ Thursday, February 7, 2019

**LEGIBLY PRINT OR TYPE YOUR NAME HERE:**  
 (REQUIRED in order to receive CME credit)

- |   |
|---|
| 1. Identify current treatment modalities for tumors related to HPV and gain insight into novel approaches by evaluating targetable mutations        |
| 2. Describe innovative techniques to evaluate or monitor response to treatment in HPV related malignancies.   |
| 3. Discuss the role of immunotherapy in HPV related diseases including the employment of new technology/approaches                                  |
| 4. Review management options for radiation toxicities and discuss opportunities to prevent HPV malignancies with vaccines and behavior modification |

Would you be interested in receiving a copy of the Symposium video if made available?      Yes                      No

**OVERALL MEETING SUMMARY**

On a scale of 1 (*strongly disagree*) to 5 (*strongly agree*) please state your level of agreement with the following statements: Please choose from the drop down list.

<i>Strongly Disagree</i>	<i>Disagree</i>	<i>Neutral</i>	<i>Agree</i>	<i>Strongly Agree &gt;</i>
<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>

1. Overall, this activity was excellent
  
2. Program topics and content met the stated objectives
  
3. Content was relevant to your educational needs
  
4. Educational Format was conducive to learning
  
5. Acquired knowledge will be applied in your practice environment
  
6. Program was fair, objective, and unbiased toward any product or program

If you answered #6 with a "strongly disagree" Please explain

---

**SESSION I: TCGA and the state of HPV related malignancies**

**Moderator: John Hays, MD**

Speakers:

Please rate the teaching effectiveness of each speaker

**Please use the drop down list**

**1-Poor - 2-Needs Improvement 3-Fair 4-Great 5- Excellent**

D. Neil  
Hayes, MD

Charles  
Kunos, MD, PhD

Krishnansu  
Tewari, MD

Lisa  
Kachnic, MD

Maura  
Gillison, MD, PhD

Effective in presenting material
Speaker has expertise on the topic
Presentation was well organized and speaker was well-prepared
Presentation was fair, objective, and avoided commercial bias or influence
Discussion points were stated at the onset and well developed by the speaker

**SESSION II: NOVEL IMMUNOTHERAPY**

**Moderator: Charles Leath, MD and Ritu Salani, MD**

Speakers:

Please rate the effectiveness of each speaker

**Please use the drop down list**

**1-Poor - 2-Needs Improvement 3-Fair 4- Great 5-Excellent**

Christine Hinrichs, MD

Warner Huh, MD

Katherine Moxely, MD

Effective in presenting material
Speaker has expertise on the topic
Presentation was well organized and speaker was well- prepared
Presentation was fair, objective, and avoided commercial bias or influence
Discussion points were stated at the onset and well developed by the speaker

**SESSION III: Prognostic evaluation**

**Moderator: Elizabeth Kidd, MD**

Speakers:

Please rate the teaching effectiveness of each speaker **Please use**

**the drop down list**

**1-Poor - 2-Needs Improvement 3-Fair 4-Great 5-Excellent**

Sue Yom MD, PhD

Scott Bratmand, MD,

Julie Schwarz, MD, PhD

Effective in presenting material
Speaker has expertise on the topic
Presentation was well organized and speaker was well-prepared
Presentation was fair, objective, and avoided commercial bias or influence
Discussion points were stated at the onset and well developed by the speaker

**Session IV: Patient focused outcomes**  
**Moderator: Jennifer Young-Pierce, MD**

<p>Speakers:  Please rate the teaching effectiveness of each speaker regarding the topic.  <b>1-Poor - 2- Needs Improvement 3-Fair 4-Great 5-Excellent</b></p>
Effective in presenting material
Speaker has expertise on the topic
Presentation was well organized and speaker was well-prepared
Presentation was fair, objective, and avoided commercial bias or influence
Discussion points were stated at the onset and well developed by the speaker

Carryn Anderson, MD

Cornelia Trimble, MD

Dana Chase, MD

**What strategies/changes do you plan to implement into your practice? (Mark all that apply)**

I will Improve communication with my patients

Share with others in my practice the information learned in this activity

Patient counseling and enrollment trials

Increase Screening

This activity will not change my strategies/skills

I gained new strategies/skills from this activity

Other

**Do you anticipate any BARRIERS to your implementing any changes to your practice? (Mark all that apply)**

Knowledge

No Barriers

Cost effective

Policy issues

Staff or other System resources

Reimbursement Issues & Funding

Other

**How would you compare your educational experience with other CME activities in the past 12 months**

Excellent

Great

Neutral

Needs Improvement

Needs serious Improvement

Other

The educational goals of our CME program are committed to: Increase the capacity of Physicians and allied Health professionals to utilize research outcomes in the treatment of patients; and increase the capacity of our multidisciplinary member to design and conduct high-quality research related to gender-specific malignancies including gynecologic, breast and prostate cancers and on localized or locally advanced cancers of all types: Did this CME activity meet the mission" YES NO

Did you find any portion of this CME activity commercially biased (promotional instead of educational)?

YES

NO

If you feel there has been commercial bias, please explain:

Do you have any suggestions for future topics that would enhance your learning; objectives

**Thank You**